Cagrilintide + GLP1-S: 10 mg total blend

Buy Cagrilintide + Semaglutide blend, listed here as Cagrilintide + GLP1-S, with 5 mg of each compound and 10 mg total labeled material. It is supplied as lyophilized powder in one boxed 3 mL vial for laboratory research. The original laboratory report identifies GLP1-S as semaglutide.

Choose a blend or separate materials

The 10 mg label is the combined amount, not 10 mg of each ingredient. This is one premixed vial, not a kit containing two separate vials.

For work that requires independent component controls or a different ratio, compare the Cagrilintide 5 mg and GLP1-S 5 mg single-compound listings. A premix fixes the labeled component ratio and should be evaluated as its own preparation.

Two components with different research backgrounds

Kruse and colleagues describe Cagrilintide development as a modified amylin analog. Lau and colleagues describe the structure-based development of semaglutide, a GLP-1 receptor analog. These studies concern the individual compounds.

Neither paper establishes stability, component recovery or biological activity for this commercial premix. A study of separately administered compounds or another formulated combination is not a direct test of this 5 mg + 5 mg powder.

Review component-specific testing

In COA & Documents, match the lot and inspect which ingredients and measurements the report covers. Keep the labeled composition above separate from measured-content results. One overall chromatographic purity percentage does not, by itself, quantify both components.

The 3 mL capacity describes the vial, not a supplied liquid volume or reconstitution instruction. Follow applicable product records and laboratory procedures for handling and preparation.